Related Experiment Video
Updated: Jul 14, 2026
09:41
An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells
Published on: July 15, 2015
Clinical trial designs for multiple myeloma.
1Cancer Research and Biostatistics, Seattle, WA 98195, USA. antjeh@crab.org
Clinical Advances in Hematology & Oncology : H&O
|July 4, 2007
Summary
New anti-myeloma agents require updated clinical trial designs. This study addresses challenges with cytostatic agents in phase I, II, and III trials, focusing on dose toxicity and novel endpoints for better myeloma treatment evaluation.
Area of Science:
- Oncology
- Clinical Trial Design
- Pharmacology
Background:
- Conventional chemotherapy for myeloma is being supplemented by novel anti-myeloma agents with distinct mechanisms of action.
- This shift necessitates a re-evaluation of clinical trial designs, particularly for cytostatic agents.
Purpose of the Study:
- To discuss critical design issues for phase I, II, and III clinical trials involving cytostatic agents for myeloma.
- To explore alternative endpoints beyond tumor response for cytostatic agents and present trial designs for phase III studies.
Main Methods:
- Discussion of dose-toxicity curve characteristics for cytotoxic versus cytostatic agents.
- Analysis of endpoint appropriateness for phase II myeloma trials.
- Presentation of phase III clinical trial designs addressing overall efficacy and biomarker-defined subsets.
Main Results:
- Traditional phase I trial designs based on monotone dose-toxicity curves may not apply to cytostatic agents.
- Endpoints other than tumor shrinkage are crucial for evaluating cytostatic agents that stabilize disease.
- Phase III designs can be adapted to assess efficacy in the general patient population and specific biomarker-defined subgroups.
Conclusions:
- Clinical trial designs for myeloma must evolve to accommodate cytostatic agents.
- Novel endpoints and adaptive designs are essential for accurately assessing the efficacy of new anti-myeloma therapies.
- Biomarker-driven trial designs can optimize the evaluation of targeted therapies in myeloma.
Related Concept Videos
01:15Bioequivalence Experimental Study Designs: Repeated Measures, Cross-Over, Carry-Over, and Latin Square Designs
Bioequivalence experimental study designs play a pivotal role in testing the effectiveness of various treatments. Key among these are the repeated measures, cross-over, carry-over, and Latin square designs. In the repeated measures design, each subject receives all treatments, allowing for temporal comparisons. This type of design is useful in reducing variability but requires careful planning to avoid bias.The cross-over design, an economical method, involves sequential administration of...
01:16Clinical Trials
Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
There are four phases in a clinical trial. A phase one...
01:11Clinical Trials: Overview
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
01:11Bioavailability Study Design: Single Versus Multiple Dose Studies
Bioavailability studies are essential for understanding how a drug is absorbed, distributed, metabolized, and excreted in the body. These studies assess the extent and rate at which the active pharmaceutical agent becomes available at the site of action. The design of bioavailability studies can involve single-dose or multiple-dose regimens, each with distinct advantages and limitations.Single-dose studies are the preferred approach due to their simplicity and reduced drug exposure for...
01:20Bioequivalence Experimental Study Designs: Completely Randomized and Randomized Block Designs
Bioequivalence experimental study designs are crucial methodologies used in evaluating and comparing the bioavailability of different drug products. These designs are categorized into various types: completely randomized, randomized block, repeated measures, cross and carry-over, and Latin square designs.Completely randomized designs involve randomly allocating treatments to all subjects participating in the experiment. This allocation is achieved by assigning unique random numbers to subjects...
01:15Bioavailability Study Design: Healthy Subjects Versus Patients
Bioavailability studies are essential for evaluating a drug's therapeutic efficacy and understanding its absorption patterns under various physiological conditions. Conducting such studies on target patient populations provides more relevant data by simulating real-world disease states. However, practical challenges often necessitate the use of young, healthy adult volunteers as study subjects.Patients may exhibit altered drug absorption patterns due to the effects of the disease itself,...